Table 3 Prognostic factors in patients with metastatic HCC treated with TACE or TACE and sorafenib in combination

Age

1.01

0.98 – 1.04

0.725

gender (male vs. female)

2.27

1.00 – 5.11

0.048

2.39

0.99 – 5.76

0.052

Intrahepatic tumor expansion (multifocal vs. oligododular)

1.95

1.07 – 3.55

0.028

1.86

0.99 – 3.47

0.031

Tumor size (cm)

1.02

0.95 - 1.10

0.527

Sorafenib

0.89

0.51 – 1.56

0.688

ALBI

0.769

 ALBI 1

1

 ALBI 2

1.24

0.69 – 2.24

0.468

 ALBI 3

1.16

0.46 – 2.94

0.761

viral vs. non-viral etiology

1.03

0.60 – 1.76

0.923

segmental portal vein thrombosis

2.10

1.04 – 4.24

0.038

AFP > 400 ng/ml

1.16

0.68 - 2.00

0.582

ECOG

 0

1

 1

0.91

0.43 – 1.95

 2

2.60

0.91 7.48

multiple metastases

0.99

0.48 – 2.04

0.981